Show simple item record

dc.contributor.authorCastelo-Branco, L
dc.contributor.authorTsourti, Z
dc.contributor.authorGennatas, S
dc.contributor.authorRogado, J
dc.contributor.authorSekacheva, M
dc.contributor.authorViñal, D
dc.contributor.authorLee, R
dc.contributor.authorCroitoru, A
dc.contributor.authorVitorino, M
dc.contributor.authorKhallaf, S
dc.contributor.authorŠušnjar, S
dc.contributor.authorSoewoto, W
dc.contributor.authorCardeña, A
dc.contributor.authorDjerouni, M
dc.contributor.authorRossi, M
dc.contributor.authorAlonso-Gordoa, T
dc.contributor.authorNgelangel, C
dc.contributor.authorWhisenant, JG
dc.contributor.authorChoueiri, TK
dc.contributor.authorDimopoulou, G
dc.contributor.authorPradervand, S
dc.contributor.authorArnold, D
dc.contributor.authorHarrington, K
dc.contributor.authorMichielin, O
dc.contributor.authorDafni, U
dc.contributor.authorPentheroudakis, G
dc.contributor.authorPeters, S
dc.contributor.authorRomano, E
dc.coverage.spatialEngland
dc.date.accessioned2022-07-13T14:01:55Z
dc.date.available2022-07-13T14:01:55Z
dc.date.issued2022-05-08
dc.identifier100499
dc.identifierS2059-7029(22)00119-3
dc.identifier.citationESMO Open, 2022, 7 (3), pp. 100499 -en_US
dc.identifier.issn2059-7029
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5226
dc.identifier.eissn2059-7029
dc.identifier.eissn2059-7029
dc.identifier.doi10.1016/j.esmoop.2022.100499
dc.identifier.doi10.1016/j.esmoop.2022.100499
dc.description.abstractBACKGROUND: ESMO COVID-19 and CAncer REgistry (ESMO-CoCARE) is an international collaborative registry-based, cohort study gathering real-world data from Europe, Asia/Oceania and Africa on the natural history, management and outcomes of patients with cancer infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). PATIENTS AND METHODS: ESMO-CoCARE captures information on patients with solid/haematological malignancies, diagnosed with coronavirus disease 2019 (COVID-19). Data collected since June 2020 include demographics, comorbidities, laboratory measurements, cancer characteristics, COVID-19 clinical features, management and outcome. Parameters influencing COVID-19 severity/recovery were investigated as well as factors associated with overall survival (OS) upon SARS-CoV-2 infection. RESULTS: This analysis includes 1626 patients from 20 countries (87% from 24 European, 7% from 5 North African, 6% from 8 Asian/Oceanian centres), with COVID-19 diagnosis from January 2020 to May 2021. Median age was 64 years, with 52% of female, 57% of cancer stage III/IV and 65% receiving active cancer treatment. Nearly 64% patients required hospitalization due to COVID-19 diagnosis, with 11% receiving intensive care. In multivariable analysis, male sex, older age, Eastern Cooperative Oncology Group (ECOG) performance status ≥2, body mass index (BMI) <25 kg/m2, presence of comorbidities, symptomatic disease, as well as haematological malignancies, active/progressive cancer, neutrophil-to-lymphocyte ratio (NLR) ≥6 and OnCovid Inflammatory Score ≤40 were associated with COVID-19 severity (i.e. severe/moderate disease requiring hospitalization). About 98% of patients with mild COVID-19 recovered, as opposed to 71% with severe/moderate disease. Advanced cancer stage was an additional adverse prognostic factor for recovery. At data cut-off, and with median follow-up of 3 months, the COVID-19-related death rate was 24.5% (297/1212), with 380 deaths recorded in total. Almost all factors associated with COVID-19 severity, except for BMI and NLR, were also predictive of inferior OS, along with smoking and non-Asian ethnicity. CONCLUSIONS: Selected patient and cancer characteristics related to sex, ethnicity, poor fitness, comorbidities, inflammation and active malignancy predict for severe/moderate disease and adverse outcomes from COVID-19 in patients with cancer.
dc.formatPrint-Electronic
dc.format.extent100499 -
dc.languageeng
dc.language.isoengen_US
dc.publisherElsevier BVen_US
dc.relation.ispartofESMO Open
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectcancer
dc.subjectoncology
dc.titleCOVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE).en_US
dc.typeJournal Article
dcterms.dateAccepted2022-04-23
dc.date.updated2022-07-13T13:57:00Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1016/j.esmoop.2022.100499en_US
rioxxterms.licenseref.startdate2022-05-08
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35644101
pubs.issue3
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/ImmNet
pubs.publication-statusPublished online
pubs.volume7
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevin
icr.provenanceDeposited by Mr Arek Surman on 2022-07-13. Deposit type is initial. No. of files: 1. Files: COVID-19 in patients with cancer first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE).pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/